

accompany this response. Also filed herewith is a Request for Continued Examination and the associated fee.

IN THE CLAIMS:

Please amend claims 7 and 14 and add new claim 22 as follows.

Applicants' representative has attached the claims with markings to show changes made in an appendix.

C1

7. An intranasal formulation as in claim 1, wherein said scopolamine is provided as a chemically modified equivalent selected from scopolamine bromide, scopolammonium bromide, scopolamine hydrochloride, methscopolamine bromide, or methscopolamine nitrate, or a pharmaceutically acceptable salt thereof.

C2

14. A method of preventing and/or treating nausea and/or vomiting comprising administering intranasally to a mammal an effective amount of scopolamine or a pharmaceutical salt thereof in a pharmaceutically acceptable carrier at a pH below about 4.0 and a buffer salt concentration below about 200 mM, said carrier incorporating polyvinyl alcohol.

C3

22. The method of claim 14, wherein said scopolamine is provided as a chemically modified equivalent selected from scopolamine bromide, scopolammonium bromide, scopolamine hydrochloride, methscopolamine bromide, or methscopolamine nitrate, or said pharmaceutically acceptable salt thereof.